Investors
Low-cost Latin American production. High-margin European medical supply.
CannHill SAS is combining fully licensed Colombian infrastructure with precision greenhouse engineering to serve high-demand medical markets in Europe. Direct equity participation via Agritech Invest Holding BV combines Latin American cost efficiency with European legal protection and governance.
Optimal Microclimate Infrastructure
Leveraging Colombia's premier greenhouse agricultural environment to achieve world-leading cost-efficiency without compromising on quality.
Established Global Sales Channels
Immediate market access through existing distribution and marketing networks in Tier-1 medical cannabis jurisdictions, including Germany, the UK, and Australia.
Next-Generation Cultivation Facilities
Bridging the quality gap by utilizing advanced greenhouse technology that replicates indoor environmental precision at a significantly lower operational cost.
Elite Genetic Pipeline
Exclusive in-house cultivars through Paradise Seeds, supplemented by a strategic breeding network to ensure a diverse portfolio of pharma-trending genetics.
How CannHill is Structured
A European governance model supporting Colombian production and regulated pharmaceutical distribution.
Agritech Invest Holding BV
Netherlands / Parent Co.
Primary asset holder, investor equity entry point, capital management.
CannHill SAS
Colombia / Manufacturer
Cultivation, production, export license holder.
CannHill Global Distribution BV
Netherlands / Distribution
Pricing, EU-GMP oversight, captures market profit.
European Medical Markets
Pharmaceutical buyers and market price via the EU operating co.
Pre-Development
CompletedLand acquisition, licensing, pilot facility setup, genetic selection, GMP readiness.
Phase 1
Current raiseCommercial greenhouse build and post-harvest infrastructure.
Phase 2
Cash flow fundedCommercial export scale, long-term supply agreements, and site expansion.
Participate in the Capital Raise
Full financial models, buildout specifications, and valuation terms are available to qualified investors in our Investor Information Package.